

## Study: ENGOT-cx19 / eVOLVE-Cervical

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy

### MaNGO Sites:

Prov	City	Site	Principal Investigator	Active **
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
LC	Lecco	Ospedale Manzoni	Antonio Ardizzoia *	
MB	Monza	Ospedale San Gerardo	Stefania Canova	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	
RM	Roma	Ospedale Umberto I	Federica Tomao	

\* **MaNGO Principal Investigator**

\*\* **Submission in Italy: ongoing**